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Abstract
The human multidrug resistance protein (MRP) family contains at least six members: MRP1, the godfather of the family
and well known as the multidrug resistance protein, and five homologs, called MRP2^6. In this review, we summarize what is
known about the protein structure, the expression in tissues, the routing in cells, the physiological functions, the substrate
specificity, and the role in multidrug resistance of the individual members of the MRP family. ß 1999 Elsevier Science B.V.
All rights reserved.
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1. Introduction
The MRP family entered the drug resistance scene
in 1992 when Susan Cole and Roger Deeley cloned
the multidrug resistance-associated protein gene, now
known as MRP1 [1]. MRP2 followed in 1996 [2^4]
and the notion of an MRP family with ¢ve members
was introduced at the Gosau meeting on ABC trans-
porters in 1997 by Marcel Kool [5,6]. MRP6 was
added in 1998 [7,8] and the existence of a 7th family
member, MRP7, has only been inferred from a
database search. It will not be discussed any further
here.
Sequences corresponding to each of these members
of the MRP family were already identi¢ed in the
ground-breaking paper by Allikmets et al. [9], which
identi¢ed 21 new ABC transporters on the basis of
conserved sequences. Some of these MRPs are also
known by other names, as summarized in Fig. 1.
MRP2 was characterized as the canalicular multispe-
ci¢c organic anion transporter (cMOAT) long before
its cloning [10], because this transporter is missing in
rats with an inborn error in the biliary secretion of
organic anions, including the conjugated bilirubins
(see [3,11] and Ko«nig et al., this volume). Hence,
the term MOAT has also been used for other mem-
bers of the MRP family [11^14]. The sMRP [15] is a
cloning artifact and ARA [16,17] represents the 3P-
end of the MRP6 gene that is incidentally co-ampli-
¢ed with MRP1 in cells selected for doxorubicin re-
sistance [8].
Within the MRP family, homology is highest be-
Fig. 1. Overview of the MRP family and the alternative names used in the literature for the individual members.
Table 1
Percentage amino acid identity between the human MRP proteins for which the complete sequence is known
MRP1 MRP2 MRP3 MRP4 MRP5 MRP6
1531 aa chr 16 1545 aa chr 10 1527 aa chr 17 1325 aa chr 13 1437 aa chr 3 1503 aa chr 16
MRP1 100
MRP2 49 100
MRP3 58 48 100
MRP4 39 37 36 100
MRP5 34 35 33 36 100
MRP6 45 38 43 34 31 100
For the accession numbers of the MRP genes, see legend of Fig. 3.
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tween MRP1, -2, -3 and -6 (Table 1). These MRPs
also share the characteristic TMD0L0 segment
[18,19], also seen in glutathione^drug conjugate
(GS-X) pumps from simple eukaryotes, such as yeast
and Leishmania (Fig. 2). Although this segment is
absent in MRP4 and -5, it should be noted that these
still have the basic structure that seems to be re-
quired for GS-X pump activity in MRP1 [20], i.e.
the P-glycoprotein-like core structure and the L0
loop (Fig. 2).
Within the group of mammalian ABC transporters
the MRPs form a cluster that is clearly demarcated
from the other known groups, such as the P-glyco-
proteins, CFTR, and the sulfonylurea receptors (Fig.
3). Although the functions of the family members
may turn out to be diverse, for the moment it there-
fore seems reasonable to speak of an MRP family.
We focus here on the ability of MRPs to transport
anti-cancer drugs and on the physiological functions
of MRPs.
Fig. 2. Membrane topology models for MRP1 and MRP5 according to [20]. MRP2, MRP3 and MRP6 have a similar structure as
MRP1 and are characterized by the presence of the extra N-terminal extension with ¢ve transmembrane regions (TMD0) connected to
a Pgp-like core by a cytoplasmic linker (L0). MRP4 has a similar structure as MRP5. They both lack the TMD0 domain, but contain
the intracellular L0 domain in addition to the Pgp-like core.
Table 2
General features of MRPs
GS-X
pumpa
Transport of
MTXb
Transport of
(some) MDR drugsa
Main location in the bodyc KO mice (rats)
availabled
MRP1 + + + Ubiquitous (low in liver) +
MRP2 + + + Liver, kidney, gut +
MRP3 + + + Liver, adrenals, pancreas, kidney,gut 3
MRP4 ? ? ? Prostate, lung, muscle, pancreas, testis,
ovary,bladder, gallbladder,
3
MRP5 + 3? ? Ubiquitous +
MRP6 ? ? ? Liver, kidney 3
aSee other sections of this paper.
bSee [21^24].
cBased on RNA expression data [6,8,12,13,25,26,59].
dSee Section 6.
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2. General features of MRPs
Some of the general features of MRPs are sum-
marized in Table 2 and Fig. 4. MRP1, -2, -3 and -5
are able to transport glutathione conjugates, such as
dinitrophenyl glutathione (DNP-GS). For MRP4
and -6, this remains to be tested. MRP1^3 can trans-
port methotrexate (MTX) [21^24], experiments with
transfected MRP5 cells have thus far been negative.
The same holds for clinical MDR drugs, as will be
discussed in more detail below. MRP1, MRP4 and
MRP5 RNAs are widely distributed in the body,
whereas MRP2, MRP3 and MRP6 appear mainly
to function in liver, kidney and gut
[6,8,12,13,25,26]. In the case of MRP1^3, the RNA
data summarized in Table 2 have been substantiated
by protein localization. For the other MRPs no pro-
tein data are available yet.
In polarized monolayers of kidney cells, MRP2 is
routed to the apical membrane and MRP1, -3 and -5
to the basolateral membrane (Fig. 4). MRP4 and -6
have not been analyzed. With speci¢c (monoclonal)
antibodies MRP2 has also been located in apical,
and MRP1 and MRP3 in basolateral membranes of
tissues [2,23,26^28]. A substantial fraction of MRP1
of normal tissues is not in the plasma membrane, but
located in unde¢ned intracellular vesicles [2]. The
MRP5-speci¢c antibodies available thus far do not
detect MRP5 in tissue sections and the localization
of this protein in vivo remains to be sorted out.
3. Five problems in the study of MRPs and some
solutions
(1) The MRPs characterized thus far are organic
anion transporters (Table 2). Hence, many good sub-
strates for these transporters are highly charged and
do not penetrate the cell membrane. This complicates
the study of MRPs in intact cells. There are hydro-
phobic pro-drugs, however, that are converted in the
cell into anions. Examples are 1-chloro-2,4-dinitro-
benzene (CDNB) that is converted in the cell into
DNP-GS by a glutathione-S-transferase; and cal-
cein-AM that is rapidly hydrolyzed to calcein in
the cell. A disadvantage of these prodrugs is that
their conversion into MRP substrate may be limiting.
For the characterization of substrate speci¢city, it is
therefore necessary to study vesicular transport by
MRPs in inside-out vesicles. Insect Sf9 cells trans-
fected with baculovirus MRP constructs have proven
the most convenient source of such vesicles.
(2) Antibodies against one MRP often cross-react
with another member of the MRP family. This prob-
lem has been solved by generating monoclonal anti-
bodies against the non-conserved parts of MRPs and
by rigorously checking speci¢city against a panel of
di¡erent MRPs.
(3) Cells selected for drug resistance often overex-
press multiple transporter genes. Attempts to relate
the resistance pro¢le of such cells to a single trans-
porter are therefore risky. The use of speci¢c inhib-
itors or transfected cells can solve this problem. Un-
fortunately, there are no drugs yet that speci¢cally
inhibit a single MRP species without e¡ect on other
transporters. In fact, most inhibitors of MRP1 and
MRP2 studied thus far are organic anions that act as
Fig. 3. Phylogenetic rooted tree showing the relationship be-
tween the human MRP homologs, human SUR1 and SUR2,
human CFTR, and the three Pgp homologs, MDR1, MDR3
and BSEP. To generate this tree the C-terminal end of each
protein was used that aligns with amino acids 955^1531 of
MRP1. This part of the protein includes the C-terminal six
transmembrane domains as well as the second nucleotide bind-
ing domain. For the multiple sequence alignment the PILEUP
program from the University of Wisconsin Genetics Group
(GCG) package (version 9.1) was used. The following accession
numbers were used: MRP1, L05628; MRP2, U49248; MRP3,
AF009670; MRP4, AF071202; MRP5, AF104942; MRP6,
AF076622; MRP7, U66684; SUR1, L78207; SUR2, AF061289;
CFTR, M28668; MDR1, M14758; MDR3, M23234; BSEP,
AF091582.
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substrates for MRPs. Attempts have been made to
speci¢cally block only a single MRP by inhibiting its
synthesis by anti-sense oligonucleotides. Although
partial inhibition in short-term experiments has
been observed with selected cell lines ([29] and M.
Kool, unpublished data), this approach is unsuitable
for systematic studies.
The characterization of substrate speci¢city of
MRPs therefore requires cells transfected with
MRP expression constructs. By comparing the trans-
fected cell with its untransfected parent, the activity
of the MRP introduced can (in principle) be de-
duced.
(4) It has been di⁄cult to get MRP transfectants
giving high expression and product routed to the cell
membrane. Some of the initial transfection con-
structs produced low levels of transporter, but this
could be remedied by shortening the construct seg-
ment corresponding to the 5P-untranslated region of
the mRNA and improving the translational start.
Transfected cells may also lose expression over time
and it is therefore necessary to use early passages,
reclone if necessary, and regularly check expression
levels by antibody. Two serious problems remain,
however. (a) Most cells contain endogenous (organic
anion) transporters resulting in background trans-
port activity. This activity may vary somewhat by
clonal variations in expression of endogenous trans-
porters. As the endogenous transporters are often
uncharacterized and, hence, undetectable by anti-
body, e.g. in the pig and dog polarized kidney cells
often used for transport studies, there is no simple
solution for this problem. However, endogenous P-
glycoprotein may be suppressed by adding speci¢c
inhibitors, such as PSC833 [30]. We have generated
cell lines from KO mice lacking both murine P-gps
and Mrp1. These should eventually provide parental
cells with much lower background resistance/trans-
porter activities than the human cells now used for
transfection experiments. (b) Transfected cells pro-
duce a transporter that is trapped in an endosomal
compartment and does not reach the plasma mem-
brane. The problem is illustrated by the (largely, un-
published) data for MRP2 summarized in Table 3.
Some cell lines transfected with a retroviral MRP2
construct do not express the protein at all, or in a
patchy fashion with only 10% of the cells positive.
This 10% is maintained after cloning and may re£ect
a deleterious e¡ect of the transporter on cell viability.
Intra-cellular routing of MRP2 is also sensitive to
growth conditions and in kidney cells or hepatocytes
Fig. 4. Schematic representation of the localization of MDR1
Pgp, MRP1, MRP2, MRP3 and MRP5 in transfected polarized
epithelial cells. The physical barrier between the apical and ba-
solateral plasma membrane is formed by tight junctions.
Table 3
Overview of MRP2-transfected cell lines
Transfected cell Tissue of origin Expression level Fraction of positive cells MRP2 in the plasma membrane
HCT8 Colon carcinoma 3 3 3
PXN94 Ovarian carcinoma 3 3 3
SW 1573 Lung carcinoma + 10% 3
T24 Bladder carcinoma ++ 10% 3
2008 Ovarian carcinoma +++ s 75% Some
A2780 Ovarian carcinoma +++ s 75% Some
LLC-PK1 Pig kidney ++ s 90% Mosta
MDCKII Canine kidney +++ s 90% Mosta
aMRP2 is only routed to the plasma membrane when cells are growing as a monolayer.
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MRP2 only goes to the plasma membrane if cells
touch [30,31].
(5) Cells transfected with MRP1, MRP2 or MRP5
cDNAs secrete GSH into the medium and this might
be one of the reasons why it has been more di⁄cult
to get cells expressing high levels of MRP than of P-
gp. If cells transfected with an MRP1 cDNA con-
struct are transferred from rich growth medium to
bu¡ered saline, they are rapidly depleted of GSH,
suggesting that they must be producing GSH at
high rate in growth medium to counteract this drain.
We have found no simple way to stop this e¥ux or
to compensate it with glutathione esters. We return
to the mechanism of the e¥ux in the next section.
4. GSH excretion by MRP transfected cells
It was found at an early stage that the organic
anion transporter MRP1 was also able to transport
non-anionic organic drugs, such as anthracyclines
and Vinca alkaloids. Attempts to detect derivatives
of these drugs conjugated to an anionic ligand (GSH,
glucuronic acid, sulfate) have remained unsuccessful
and the consensus is now that these drugs are trans-
ported as such. Early experiments also established
that cellular resistance to these drugs mediated by
MRP1 requires intracellular GSH, suggesting that
GSH is either required as an activator or as a co-
transported substrate.
More recent experiments have shown that GSH is
required for vesicular transport of vincristine by
MRP1 and for inhibition by vincristine of the trans-
port of organic anions by MRP1 [32]. Vanadate-
mediated nucleotide trapping experiments directly
showed a low-a⁄nity binding of GSH to MRP1
[33]. These experiments did not answer the question
whether GSH is an activator or a co-transported
substrate. Recent experiments with kidney cells
transfected with a MRP2 cDNA construct have
shown, however, that vinblastine transport mediated
by MRP2 induces a proportional GSH transport.
The stoichiometry is odd, as the ratio of vinblas-
tine/GSH transported is 2^3 [34] in this system.
Nevertheless, the results strongly support a co-trans-
port model.
Another question that has remained unanswered
concerns the GSH secreted by cells transfected with
MRP1, MRP2 and MRP5 cDNA constructs. The
importance of MRP1-mediated GSH export in vivo
is obvious from the observation that Mrp1 (3/3)
mice have raised levels of GSH in their tissues [35].
Is this GSH co-transported with an endogenous li-
gand or is GSH transported by itself? MRP1 can
bind GSH with low a⁄nity, but can it also transport
GSH? The low a⁄nity of GSH for MRPs has made
it di⁄cult to study transport of radioactive GSH in
vesicles. It has been shown, however, that GSH com-
petitively inhibits uptake of other MRP1 substrates
in vesicles [36]. This is compatible with GSH trans-
port by MRP1. Important supporting evidence has
come from experiments with yeast. Rebbeor et al.
[37] have shown that yeast cadmium resistance factor
1 (Ycf1), the yeast ortholog of MRP1/2 [38], trans-
ports GSH with low a⁄nity (Km = 15 mM).
All these results and other experiments summa-
rized by Paulusma et al. [36] and Ballatori and Reb-
beor [39] support the idea that MRP1/2 can trans-
port GSH. As no endogenous ligand co-transported
with GSH has been found ([36,39] and our unpub-
lished data with cultured cells), we favor a minimal
working model [34] for MRP1/2 with two drug bind-
ing sites: one with a relatively high a⁄nity for GSH
(G-site) and a low a⁄nity for drug, and one with a
relatively high a⁄nity for drug and a low a⁄nity for
GSH (D-site). In the absence of drugs, both binding
sites are occupied by GSH resulting in a slow export
of GSH. At low drug concentrations, the G-site re-
mains occupied by GSH and the D-site becomes oc-
cupied by drug, resulting in co-transport of both
compounds. We infer that the two sites show positive
cooperativity as we observe stimulation of GSH
transport by MDCKII-MRP2 cells in the presence
of the organic anions sul¢npyrazone and indometha-
cin [34]. This may also explain why sul¢npyrazone is
able to stimulate DNP-GS export in MDCKII-
MRP2 cells [30]. At high drug concentrations some
(negatively charged) drugs appear to be able to oc-
cupy both the G- and D-site resulting in transport of
drug alone. MRP1 and MRP2 do not require free
GSH for the transport of compounds that are con-
jugated to glutathione, glucuronide or sulfate [30,40^
42]. We suggest that such substrates have a relatively
high a⁄nity for both the G- and D-site and are
therefore transported e⁄ciently without requiring
GSH or stimulating GSH export. As cells with
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high levels of MRP3 do not secrete GSH [23], the G-
site in this transporter may have a very low a⁄nity
for GSH.
5. What do MRPs contribute to drug resistance of
cancer cells?
Table 2 provides a brief summary of current
knowledge. MRP1 can cause resistance to a wide
range of MDR drugs, as discussed in detail by Hipf-
ner et al. in this volume. Hooijberg et al. [22] have
recently shown that MRP1 can also cause high level
resistance to short-term methotrexate (MTX) expo-
sure. The same was found for MRP2 and MRP3
[22,23]. MTX is transported, but the polyglutamy-
lated forms of MTX, accumulating during long ex-
posure, are not transported (our unpublished data)
and hence resistance nearly disappears during long-
term incubations. The clinical signi¢cance of the high
levels of MRP1 found in some human tumors, re-
mains to be established (see Hipfner et al., this vol-
ume).
The substrate speci¢city of MRP2 was de¢ned in
detail using natural rat mutants (TR3/GY or EHBR)
lacking MRP2, and by vesicular transport studies
(see Ko«nig et al., this volume). However, only some
MDR drugs were included in these studies. More
recently, we observed that the variable expression
of MRP2 in lung cancer cells selected for doxorubi-
cin resistance, correlated very well with resistance to
cisplatin [6]. This was of interest as Ishikawa and
coworkers had already shown that cisplatin and
GSH can form a 1:2 complex that might be removed
from cells by a GS-X pump [43]. The complex was
shown to inhibit LTC4 transport by MRP1 [44], but
all attempts to demonstrate cisplatin resistance in
MRP1-transfected cells were unsuccessful (see Hipf-
ner et al., this volume).
Recent results have shown, however, that MRP2
can confer resistance to cisplatin, in addition to a
range of MDR drugs. Koike et al. used a stable
anti-sense cDNA construct of MRP2 to transfect
the human HepG2 hepatoma cell line [45]. This re-
sulted in sensitization to a remarkable series of
drugs: cisplatin, CPT-11, the camptothecin deriva-
tive SN-38, vincristine and doxorubicin. It also led
to a substantial decrease in MRP2 and to a 4-fold
increase in cellular GSH [45]. Since the anti-sense
construct was rather long (805 bp) it is not com-
pletely excluded that these remarkably strong e¡ects
on resistance could have been due to inhibition of the
synthesis of several di¡erent MRPs.
Recent transfection experiments have substanti-
ated the ability of MRP2 to transport the Vinca al-
kaloid vinblastine [30]. The study of drug resistance
in transfected cells was complicated, however, by low
levels of MRP2 expression and poor routing to the
plasma membrane (Table 3). In the best transfec-
tants, 2008 ovarium carcinoma cells, we only ob-
served marginal resistance to vincristine and mitox-
antrone (M. Kool, unpublished data). However, Cui
et al. [46] succeeded in getting su⁄cient expression of
MRP2 in human embryonic kidney (HEK-293) and
MDCK cells to demonstrate clear, i.e. 5- to 10-fold,
resistance to etoposide, vincristine, doxorubicin and
cisplatin (see further discussion by Ko«nig et al., this
volume). These results establish the ability of MRP2
to confer resistance to cisplatin and a range of MDR
drugs. It remains to be seen whether this ever occurs
in patients.
Early studies on MRP3 did not ¢nd any correla-
tion between expression of this transporter and drug
resistance [6]. A more recent survey of a panel of
lung cancer cell lines showed, however, a strong cor-
relation between MRP3 and doxorubicin resistance
and a weaker, but still highly signi¢cant correlation
with resistance to vincristine, etoposide and cisplatin
[47]. In an important study using MRP3-containing
vesicles from MRP3-transfected animal cells, Hiro-
hashi et al. [24] showed that MRP3 is a typical or-
ganic anion transporter, but, unlike MRP1 and -2, it
prefers glucuronides as substrates over glutathione
conjugates. Hirohashi et al. [24] also found that
MRP3 transports MTX and this was independently
shown by Kool et al. [23]. In addition, Kool et al.
[23] found low etoposide and teniposide resistance
in MRP3-transfected cells. As it is di⁄cult to gener-
ate transfected cells with high concentrations of
MRP3 in the plasma membrane, it remains possible
that higher levels of MRP3 will also result in resis-
tance to doxorubicin and possibly other drugs, as
suggested by the correlation study of Young et al.
[47].
Little is known as yet about MRP5. The intriguing
possibility that this transporter causes resistance to
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thio-purines [48] remains to be substantiated by drug
accumulation and vesicular transport studies.
6. Physiological functions of MRPs
Defense against toxic compounds is a major con-
cern of all living organisms and ABC transporters
play an essential role in this defense. The PgpA of
Leishmania, an MRP avant la lettre, because it was
discovered before MRP1, but not recognized as a
novel class of ABC transporter, contributes to the
defence of this unicellular parasite against arsenite
and antimonite [49]. In Caenorhabditis elegans,
MRPs contribute to the defence against heavy metal
ions and against some of the toxins that bacteria
produce to escape being eaten by this bacterial pred-
ator [50]. It is, therefore, likely that mammalian
MRPs also help to protect their host against toxic
compounds and studies on Mrp1 KO mice have
shown that this is indeed the case. The Mrp1
(3/3) mice are hypersensitive to etoposide [51,52],
and this is especially manifest in bone marrow,
testis, kidney, the oropharyngeal mucosa, i.e. in cells
which normally have a substantial amount of Mrp1
[53].
As Mrp1 is located at the basolateral side of epi-
thelium cells, it tends to pump drugs into the body,
rather than into bile, urine or gut for disposal, as P-
glycoprotein does. Nevertheless, Mrp1 can protect
vital cell layers from destruction, for instance, the
basal stem cell layer in the oral mucosa [53]. There
are also important organs in the body that require a
basolateral transporter for protection. A good exam-
ple are the testicular tubules. The male germ cells are
protected by a ring of Sertoli cells with their apical
surface towards the lumen. The high concentration
of Mrp1 in the basal membrane of the Sertoli cells
helps to protect the germ cells by pumping out drug
from the testicular tubule [53]. Another position in
the body where a basolateral transporter is useful for
protecting a vital organ is the choroid plexus. This
structure protrudes into the cerebrospinal £uid (CSF)
and is essential for exchange of metabolites between
blood and CSF. The epithelial cell layer of the plexus
contains a high amount of Mrp1 ([54] and our un-
published data) and we have recently shown, that the
absence or Mrp1 results in considerable accumula-
tion of intravenously administered etoposide in the
CSF (J. Wijnholds, unpublished data).
Whether MRP2^6 also play a role in protection
against exogenous toxic compounds remains to be
determined. There is no Mrp2 KO mouse, but there
are natural rat mutants lacking Mrp2. These mutant
rats are compromised in the excretion of organic
anions from the liver (see Ko«nig et al., this volume).
The Mrp5 (3/3) mouse was only recently generated
and pharmacological studies with this mutant remain
to be done (J. Wijnholds, unpublished data).
The presence of a range of ABC transporters avail-
able for defence against toxic compounds, has al-
lowed the recruitment during evolution of some of
these transporters for metabolic purposes. An exam-
ple is the MDR3 P-glycoprotein, which evolved from
a duplicate copy of the gene for a drug-transporting
P-glycoprotein into a dedicated transporter for phos-
phatidylcholine [55]. There is abundant evidence that
the MRPs also have important physiological func-
tions. MRP2 provides a major route for the secretion
of organic anions from the liver, and rats and hu-
mans lacking this transporter develop a mild liver
disease, mainly due to the inability of the liver to
excrete bilirubin-glucuronides (see Ko«nig et al., this
volume).
MRP1 is the major high-a⁄nity transporter of leu-
kotriene C4 (LTC4) as shown by biochemical experi-
ments and the analysis of KO mice [51]. Remarkably,
the absence of the major LTC4 excretion pathway
does not have any detectable deleterious e¡ect on
mice in the congenial surroundings of a quality ani-
mal house. Actually, the mice are more resistant than
wild-type mice against an in£ammatory stimulus and
even against a bacterial lung infection [51,56]. This
does not mean that MRP1 is more important for
defense than for normal metabolism. It remains pos-
sible that there is overlap in function between MRPs
and that double or triple KO mice lacking several
Mrps may reveal a more substantial metabolic role
for MRP1 than is now apparent.
The tissue distribution of MRP3 shown in Table 2
[6,13,23,25,26] and its basolateral position in pola-
rized cells [23,26] suggest that this protein has an
important metabolic role in the intestinal uptake of
organic anions and in the removal of organic acids
from bile and liver cells under conditions of choles-
tasis. Mrp3 is highly upregulated in the liver of rats
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made cholestatic by bile duct ligation [57,58] and in
cholestatic human liver [23]. MRP3 is also present at
high level in the adrenal cortex ([6] and M. Kool,
unpublished immunohistochemistry data). This raises
the possibility that MRPs are responsible for secre-
tion of some hydrophilic steroid hormone deriva-
tives, such as dehydroepiandrosterone sulfate. The
birth of the Mrp3 (3/3) mouse that should help to
clarify the physiological role of Mrp3 is eagerly
awaited.
The Mrp5 KO mouse, recently generated in our
laboratory [48], is healthy and fertile and has no
obvious macroscopic defects. This shows that Mrp5
does not have an indispensable function, but whether
it is mainly a defense protein or ful¢ls functions not
yet revealed, remains to be established.
7. Outlook
The discovery of the MRP family has considerably
broadened the study of MDR in tumor cells and has
led to widespread interest in the possible function(s)
of the members of this family in normal metabolism.
It is still impossible to assess the potential contribu-
tion of MRP1, the best studied MRP, to clinical drug
resistance and we still have a long way to go before
we know for each family member whether it helps
tumors to escape from drug treatment. Likewise, our
understanding of the role of each MRP in normal
metabolism varies from being sketchy to non-exis-
tent. Transfected cells and KO mice are providing
insight into the physiological functions of MRPs,
but it should be clear from this review that a vast
amount of work remains to be done. Eventually, KO
mice combining defects in several transporters will
have to be generated to dissect overlapping functions
and get a complete picture. Interesting years lie
ahead. Mother Cole and father Deeley can be
pleased with their thriving family.
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